Are you Dr. Kocs?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 74 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
2410 Round Rock Ave
Suite 150
Round Rock, TX 78681Phone+1 512-341-8724Fax+1 512-341-9440
Summary
- Dr. Darren Kocs, MD is an oncologist in Round Rock, Texas. He is currently licensed to practice medicine in Texas and Michigan. He is affiliated with St. David's Round Rock Medical Center.
Education & Training
- University of MichiganFellowship, Hematology and Medical Oncology, 2000 - 2003
- University of MichiganResidency, Internal Medicine, 1997 - 2000
- Weill Cornell MedicineClass of 1997
Certifications & Licensure
- TX State Medical License 2003 - 2025
- MI State Medical License 1999 - 2006
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Top Doctors:SE Texas Castle Connolly, 2013
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
- Super Doctor SuperDoctors.com
Clinical Trials
- BKM120 for Patients With PI3K-activated Tumors Start of enrollment: 2013 Mar 29
Publications & Presentations
PubMed
- 1 citationsFive-year results of a phase II trial of preoperative 5-fluorouracil, epirubicin, cyclophosphamide followed by docetaxel with capecitabine (wTX) (with trastuzumab in H...Frankie A. Holmes, Beth A. Hellerstedt, John Pippen, Svetislava J. Vukelja, Rufus P. Collea
Cancer Medicine. 2018-06-01 - 37 citationsResults of docetaxel plus oxaliplatin (DOCOX) ± cetuximab in patients with metastatic gastric and/or gastroesophageal junction adenocarcinoma: Results of a randomised ...Donald A. Richards, Darren M. Kocs, Alexander I. Spira, A. David McCollum, Sami Diab
European Journal of Cancer. 2013-09-01 - 67 citationsGemcitabine, Cisplatin, and sunitinib for metastatic urothelial carcinoma and as preoperative therapy for muscle-invasive bladder cancer.Matthew D. Galsky, Noah M. Hahn, Thomas Powles, Beth A. Hellerstedt, Seth P. Lerner
Clinical Genitourinary Cancer. 2013-06-01
Professional Memberships
- Member